img

Global Orphan Drugs for Adults Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Orphan Drugs for Adults Market Research Report 2024

Orphan drugs for adults refer to medications that are specifically developed and approved for the treatment of rare diseases or conditions in adult populations. These drugs are designed to address medical needs in adult patients who have limited treatment options due to the rarity of their conditions.
According to MRAResearch’s new survey, global Orphan Drugs for Adults market is projected to reach US$ 106140 million in 2033, increasing from US$ 55670 million in 2022, with the CAGR of 9.6% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orphan Drugs for Adults market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Orphan Drugs for Adults market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Bristol-Myers Squibb Company
Roche Holding
Sanofi
Takeda
Pfizer
Vertex Pharmaceuticals
Segment by Type
Oncology Drugs
Gastrointestinal Drugs
Neurology Drugs
Cardio-vascular Drugs
Others

Segment by Application


Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Orphan Drugs for Adults report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs for Adults Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Oncology Drugs
1.2.3 Gastrointestinal Drugs
1.2.4 Neurology Drugs
1.2.5 Cardio-vascular Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Orphan Drugs for Adults Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital Pharmacies
1.3.3 Retail pharmacies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs for Adults Market Perspective (2018-2033)
2.2 Orphan Drugs for Adults Growth Trends by Region
2.2.1 Global Orphan Drugs for Adults Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Orphan Drugs for Adults Historic Market Size by Region (2018-2023)
2.2.3 Orphan Drugs for Adults Forecasted Market Size by Region (2024-2033)
2.3 Orphan Drugs for Adults Market Dynamics
2.3.1 Orphan Drugs for Adults Industry Trends
2.3.2 Orphan Drugs for Adults Market Drivers
2.3.3 Orphan Drugs for Adults Market Challenges
2.3.4 Orphan Drugs for Adults Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Drugs for Adults Players by Revenue
3.1.1 Global Top Orphan Drugs for Adults Players by Revenue (2018-2023)
3.1.2 Global Orphan Drugs for Adults Revenue Market Share by Players (2018-2023)
3.2 Global Orphan Drugs for Adults Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Drugs for Adults Revenue
3.4 Global Orphan Drugs for Adults Market Concentration Ratio
3.4.1 Global Orphan Drugs for Adults Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs for Adults Revenue in 2022
3.5 Orphan Drugs for Adults Key Players Head office and Area Served
3.6 Key Players Orphan Drugs for Adults Product Solution and Service
3.7 Date of Enter into Orphan Drugs for Adults Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs for Adults Breakdown Data by Type
4.1 Global Orphan Drugs for Adults Historic Market Size by Type (2018-2023)
4.2 Global Orphan Drugs for Adults Forecasted Market Size by Type (2024-2033)
5 Orphan Drugs for Adults Breakdown Data by Application
5.1 Global Orphan Drugs for Adults Historic Market Size by Application (2018-2023)
5.2 Global Orphan Drugs for Adults Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Orphan Drugs for Adults Market Size (2018-2033)
6.2 North America Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Orphan Drugs for Adults Market Size by Country (2018-2023)
6.4 North America Orphan Drugs for Adults Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Orphan Drugs for Adults Market Size (2018-2033)
7.2 Europe Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Orphan Drugs for Adults Market Size by Country (2018-2023)
7.4 Europe Orphan Drugs for Adults Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs for Adults Market Size (2018-2033)
8.2 Asia-Pacific Orphan Drugs for Adults Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2018-2023)
8.4 Asia-Pacific Orphan Drugs for Adults Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Orphan Drugs for Adults Market Size (2018-2033)
9.2 Latin America Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Orphan Drugs for Adults Market Size by Country (2018-2023)
9.4 Latin America Orphan Drugs for Adults Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs for Adults Market Size (2018-2033)
10.2 Middle East & Africa Orphan Drugs for Adults Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2018-2023)
10.4 Middle East & Africa Orphan Drugs for Adults Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbvie
11.1.1 Abbvie Company Detail
11.1.2 Abbvie Business Overview
11.1.3 Abbvie Orphan Drugs for Adults Introduction
11.1.4 Abbvie Revenue in Orphan Drugs for Adults Business (2018-2023)
11.1.5 Abbvie Recent Development
11.2 Orpharma
11.2.1 Orpharma Company Detail
11.2.2 Orpharma Business Overview
11.2.3 Orpharma Orphan Drugs for Adults Introduction
11.2.4 Orpharma Revenue in Orphan Drugs for Adults Business (2018-2023)
11.2.5 Orpharma Recent Development
11.3 Amgen
11.3.1 Amgen Company Detail
11.3.2 Amgen Business Overview
11.3.3 Amgen Orphan Drugs for Adults Introduction
11.3.4 Amgen Revenue in Orphan Drugs for Adults Business (2018-2023)
11.3.5 Amgen Recent Development
11.4 Recordati
11.4.1 Recordati Company Detail
11.4.2 Recordati Business Overview
11.4.3 Recordati Orphan Drugs for Adults Introduction
11.4.4 Recordati Revenue in Orphan Drugs for Adults Business (2018-2023)
11.4.5 Recordati Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Orphan Drugs for Adults Introduction
11.5.4 Novartis Revenue in Orphan Drugs for Adults Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Orphan Drugs for Adults Introduction
11.6.4 Celgene Revenue in Orphan Drugs for Adults Business (2018-2023)
11.6.5 Celgene Recent Development
11.7 Amryt Pharma
11.7.1 Amryt Pharma Company Detail
11.7.2 Amryt Pharma Business Overview
11.7.3 Amryt Pharma Orphan Drugs for Adults Introduction
11.7.4 Amryt Pharma Revenue in Orphan Drugs for Adults Business (2018-2023)
11.7.5 Amryt Pharma Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Orphan Drugs for Adults Introduction
11.8.4 Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2018-2023)
11.8.5 Johnson & Johnson Recent Development
11.9 GSK
11.9.1 GSK Company Detail
11.9.2 GSK Business Overview
11.9.3 GSK Orphan Drugs for Adults Introduction
11.9.4 GSK Revenue in Orphan Drugs for Adults Business (2018-2023)
11.9.5 GSK Recent Development
11.10 Bristol-Myers Squibb Company
11.10.1 Bristol-Myers Squibb Company Company Detail
11.10.2 Bristol-Myers Squibb Company Business Overview
11.10.3 Bristol-Myers Squibb Company Orphan Drugs for Adults Introduction
11.10.4 Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2018-2023)
11.10.5 Bristol-Myers Squibb Company Recent Development
11.11 Roche Holding
11.11.1 Roche Holding Company Detail
11.11.2 Roche Holding Business Overview
11.11.3 Roche Holding Orphan Drugs for Adults Introduction
11.11.4 Roche Holding Revenue in Orphan Drugs for Adults Business (2018-2023)
11.11.5 Roche Holding Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Detail
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Orphan Drugs for Adults Introduction
11.12.4 Sanofi Revenue in Orphan Drugs for Adults Business (2018-2023)
11.12.5 Sanofi Recent Development
11.13 Takeda
11.13.1 Takeda Company Detail
11.13.2 Takeda Business Overview
11.13.3 Takeda Orphan Drugs for Adults Introduction
11.13.4 Takeda Revenue in Orphan Drugs for Adults Business (2018-2023)
11.13.5 Takeda Recent Development
11.14 Pfizer
11.14.1 Pfizer Company Detail
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Orphan Drugs for Adults Introduction
11.14.4 Pfizer Revenue in Orphan Drugs for Adults Business (2018-2023)
11.14.5 Pfizer Recent Development
11.15 Vertex Pharmaceuticals
11.15.1 Vertex Pharmaceuticals Company Detail
11.15.2 Vertex Pharmaceuticals Business Overview
11.15.3 Vertex Pharmaceuticals Orphan Drugs for Adults Introduction
11.15.4 Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2018-2023)
11.15.5 Vertex Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Orphan Drugs for Adults Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Oncology Drugs
Table 3. Key Players of Gastrointestinal Drugs
Table 4. Key Players of Neurology Drugs
Table 5. Key Players of Cardio-vascular Drugs
Table 6. Key Players of Others
Table 7. Global Orphan Drugs for Adults Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Orphan Drugs for Adults Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Orphan Drugs for Adults Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Orphan Drugs for Adults Market Share by Region (2018-2023)
Table 11. Global Orphan Drugs for Adults Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Orphan Drugs for Adults Market Share by Region (2024-2033)
Table 13. Orphan Drugs for Adults Market Trends
Table 14. Orphan Drugs for Adults Market Drivers
Table 15. Orphan Drugs for Adults Market Challenges
Table 16. Orphan Drugs for Adults Market Restraints
Table 17. Global Orphan Drugs for Adults Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Orphan Drugs for Adults Market Share by Players (2018-2023)
Table 19. Global Top Orphan Drugs for Adults Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs for Adults as of 2022)
Table 20. Ranking of Global Top Orphan Drugs for Adults Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Orphan Drugs for Adults Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Orphan Drugs for Adults Product Solution and Service
Table 24. Date of Enter into Orphan Drugs for Adults Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Orphan Drugs for Adults Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Orphan Drugs for Adults Revenue Market Share by Type (2018-2023)
Table 28. Global Orphan Drugs for Adults Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Orphan Drugs for Adults Revenue Market Share by Type (2024-2033)
Table 30. Global Orphan Drugs for Adults Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Orphan Drugs for Adults Revenue Market Share by Application (2018-2023)
Table 32. Global Orphan Drugs for Adults Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Orphan Drugs for Adults Revenue Market Share by Application (2024-2033)
Table 34. North America Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Orphan Drugs for Adults Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Orphan Drugs for Adults Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Orphan Drugs for Adults Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Orphan Drugs for Adults Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Orphan Drugs for Adults Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Orphan Drugs for Adults Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Orphan Drugs for Adults Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Orphan Drugs for Adults Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Orphan Drugs for Adults Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Orphan Drugs for Adults Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Orphan Drugs for Adults Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Orphan Drugs for Adults Market Size by Country (2024-2033) & (US$ Million)
Table 49. Abbvie Company Detail
Table 50. Abbvie Business Overview
Table 51. Abbvie Orphan Drugs for Adults Product
Table 52. Abbvie Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 53. Abbvie Recent Development
Table 54. Orpharma Company Detail
Table 55. Orpharma Business Overview
Table 56. Orpharma Orphan Drugs for Adults Product
Table 57. Orpharma Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 58. Orpharma Recent Development
Table 59. Amgen Company Detail
Table 60. Amgen Business Overview
Table 61. Amgen Orphan Drugs for Adults Product
Table 62. Amgen Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 63. Amgen Recent Development
Table 64. Recordati Company Detail
Table 65. Recordati Business Overview
Table 66. Recordati Orphan Drugs for Adults Product
Table 67. Recordati Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 68. Recordati Recent Development
Table 69. Novartis Company Detail
Table 70. Novartis Business Overview
Table 71. Novartis Orphan Drugs for Adults Product
Table 72. Novartis Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 73. Novartis Recent Development
Table 74. Celgene Company Detail
Table 75. Celgene Business Overview
Table 76. Celgene Orphan Drugs for Adults Product
Table 77. Celgene Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 78. Celgene Recent Development
Table 79. Amryt Pharma Company Detail
Table 80. Amryt Pharma Business Overview
Table 81. Amryt Pharma Orphan Drugs for Adults Product
Table 82. Amryt Pharma Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 83. Amryt Pharma Recent Development
Table 84. Johnson & Johnson Company Detail
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Orphan Drugs for Adults Product
Table 87. Johnson & Johnson Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. GSK Company Detail
Table 90. GSK Business Overview
Table 91. GSK Orphan Drugs for Adults Product
Table 92. GSK Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 93. GSK Recent Development
Table 94. Bristol-Myers Squibb Company Company Detail
Table 95. Bristol-Myers Squibb Company Business Overview
Table 96. Bristol-Myers Squibb Company Orphan Drugs for Adults Product
Table 97. Bristol-Myers Squibb Company Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 98. Bristol-Myers Squibb Company Recent Development
Table 99. Roche Holding Company Detail
Table 100. Roche Holding Business Overview
Table 101. Roche Holding Orphan Drugs for Adults Product
Table 102. Roche Holding Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 103. Roche Holding Recent Development
Table 104. Sanofi Company Detail
Table 105. Sanofi Business Overview
Table 106. Sanofi Orphan Drugs for Adults Product
Table 107. Sanofi Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 108. Sanofi Recent Development
Table 109. Takeda Company Detail
Table 110. Takeda Business Overview
Table 111. Takeda Orphan Drugs for Adults Product
Table 112. Takeda Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 113. Takeda Recent Development
Table 114. Pfizer Company Detail
Table 115. Pfizer Business Overview
Table 116. Pfizer Orphan Drugs for Adults Product
Table 117. Pfizer Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 118. Pfizer Recent Development
Table 119. Vertex Pharmaceuticals Company Detail
Table 120. Vertex Pharmaceuticals Business Overview
Table 121. Vertex Pharmaceuticals Orphan Drugs for Adults Product
Table 122. Vertex Pharmaceuticals Revenue in Orphan Drugs for Adults Business (2018-2023) & (US$ Million)
Table 123. Vertex Pharmaceuticals Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Orphan Drugs for Adults Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Orphan Drugs for Adults Market Share by Type: 2022 VS 2033
Figure 3. Oncology Drugs Features
Figure 4. Gastrointestinal Drugs Features
Figure 5. Neurology Drugs Features
Figure 6. Cardio-vascular Drugs Features
Figure 7. Others Features
Figure 8. Global Orphan Drugs for Adults Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Orphan Drugs for Adults Market Share by Application: 2022 VS 2033
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Orphan Drugs for Adults Report Years Considered
Figure 14. Global Orphan Drugs for Adults Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Orphan Drugs for Adults Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Orphan Drugs for Adults Market Share by Region: 2022 VS 2033
Figure 17. Global Orphan Drugs for Adults Market Share by Players in 2022
Figure 18. Global Top Orphan Drugs for Adults Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs for Adults as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Orphan Drugs for Adults Revenue in 2022
Figure 20. North America Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Orphan Drugs for Adults Market Share by Country (2018-2033)
Figure 22. United States Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Orphan Drugs for Adults Market Share by Country (2018-2033)
Figure 26. Germany Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Orphan Drugs for Adults Market Share by Region (2018-2033)
Figure 34. China Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Orphan Drugs for Adults Market Share by Country (2018-2033)
Figure 42. Mexico Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Orphan Drugs for Adults Market Share by Country (2018-2033)
Figure 46. Turkey Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Orphan Drugs for Adults Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Abbvie Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 49. Orpharma Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 50. Amgen Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 51. Recordati Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 52. Novartis Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 53. Celgene Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 54. Amryt Pharma Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 55. Johnson & Johnson Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 56. GSK Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 57. Bristol-Myers Squibb Company Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 58. Roche Holding Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 59. Sanofi Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 60. Takeda Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 61. Pfizer Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 62. Vertex Pharmaceuticals Revenue Growth Rate in Orphan Drugs for Adults Business (2018-2023)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed